TSH Biopharm Corporation Ltd

People are pursuing health all their lives to protect the family, and to have a better quality of life. We are committed to providing quality health services throughout medical treatment. We are TSH. #FOCUSING With patients at our core, through the development of preventive medical services, we ensure precise medication and efficient tracking during cancer treatment and strive to improve the quality of life for patients whose medical needs have not yet been met. #SPECIALIZING We continue to grow our portfolio of medical products to treat chronic disease through the research and development of new ingredients and special formulations of new drugs. Meanwhile, we co-development genetic testing and devise innovative methods of cancer detection and post-operation therapy, as well as tumor tracking. #BECOMING Our team focuses on the development of drugs with economic benefits. TSH is your best partner for the development and marketing of new drugs in Asia. #TowardSuperiorHealth TSH closely follows prevention, treatment, and tracking, before, during, and after medical treatment. We walk together, on your path toward superior health.

TSH Biopharm's TYRVAYA® for Dry Eye Nasal Spray approved by TFDA   Taipei, Taiwan, [2024/11/18] – TSH Biopharm (TW-8432) today announced a significant milestone with the approval of TYRVAYA® for Dry Eye Nasal Spray by the Taiwan Food and Drug Administration (TFDA). This marks the second drug approval for TSH this year.   "With TYRVAYA, we are excited to offer a revolutionary new treatment option for dry eye disease patients in Taiwan," said TSH Biopharm General Manager Sze Yuan Yang. "This approval underscores our commitment to addressing unmet medical needs and further strengthens our market position."   Citing data from Fortune Business Insights, Yang noted that the global dry eye disease treatment market is poised to reach $11.3 billion by 2030, driven by a 7% compound annual growth rate. Moreover, statistics from Taiwan's Ministry of Health and Welfare indicate a substantial increase in outpatient visits for dry eye disease over the past decade.

<TBIO Activity> Vice President Hsiao met with the "2024 Taiwan BIO Award" winners on Oct. 15, acknowledging their dedication to the industry and their achievements across various fields. She emphasized that the government has continued to support the biotechnology sector through various policies in recent years, aiming to see the industry play a more critical role both in Taiwan and globally. She expressed hope for continued efforts to drive the industry's growth, making it a significant force in promoting public health. During her speech, the Vice President said she was honored to welcome the outstanding biotech companies and the representatives. She also thanked the "Taiwan Bio Industry Organization" for inviting her to attend this year's "BIO Asia–Taiwan" exhibition in July, which was an eye-opening experience. The Vice President highlighted the importance of the biotechnology industry to Taiwan, stating that through meetings and exchanges with industry professionals and scholars, as well as attending industry-related events, she has observed Taiwan's continuous progress and development in the biotech sector. Over the past few years, the government has consistently supported the industry through various policies, hoping that the biotech industry can play a more critical role both in Taiwan and on the global stage. She pointed out that due to the pandemic, there were disruptions in the global supply chain, and the world was competing for essential medical supplies. This situation underscored the complexity of global supply chains and reminded us that a strong local biotechnology industry is crucial, whether in meeting the expectations of the people or fulfilling the government's responsibility for public health. In conclusion, the Vice President congratulated all award winners for their contributions and cross-disciplinary achievements in the biotech industry, including areas such as medical devices, pharmaceuticals, research and development, agriculture, and health foods. She expressed hope for continued efforts to drive the industry's development, making it a key force in promoting public health. News Release (in Chinese): https://lnkd.in/gBCg3nZj The 2024 Taiwan BIO Award Winners: Bonraybio Corporation Lotus Pharmaceutical Co., Ltd PharmaEssentia Pharmosa Biopharm Inc TSH Biopharm Corporation Ltd Steminent Biotherapeutics Onyx Healthcare 明基透析科技 (BenQ Dialysis Technology Corp.) Acepodia ImmunAdd Inc. Sunhawk Vision Biotech (視航生物) Elixiron Immunotherapeutics BioGend Therapeutics (TWSE 6733) BRAXX Biotech Co., Ltd. Protect Animal Health Inc. Formosa Pharmaceuticals, Inc. TaiGen Biotechnology (太景生物) HippoScreen Neurotech Corp. Syngen Biotech

TSH Biopharm is leading the way in NGS. The company's liquid biopsy (pleural fluid) research, the first of its kind in Taiwan, has been published internationally and has received regulatory approval. This marks a significant milestone in the field of precision medicine. https://lnkd.in/geN_fRkH

TSH Biopharm Announces More Good News Today TSH Biopharm Chairman Chuan Lin and National Yang Ming Chiao Tung University President Chi-Hung Lin signed a five-year industry-academia collaboration memorandum of understanding (MOU) today. This collaboration focuses on two key areas: "talent cultivation" and "precision drug development". Through early validation of specific target functions and AI-assisted drug screening, the aim is to increase the success rate of new drug development, shorten time to market, and reduce costs. TSH Biopharm Chairman Chuan Lin emphasized: "A characteristic of the biomedical industry is that research and development takes a long time, but product lifecycles are also long. Therefore, cultivating outstanding talent is one of the keys to driving industry innovation. We hope to combine National Yang Ming Chiao Tung University's rich research foundation with AI-driven precision drug development, along with TSH Biopharm's product capabilities, to jointly contribute to the health and well-being of people in an aging society and establish a new paradigm for medical industry-academia collaboration in Taiwan." For complete information:https://lnkd.in/g_bPzt98

🎉🎉🎉東生華榮獲 #2024傑出生技產業獎 #潛力標竿獎 三大策略推動創新發展‼ #2024亞洲生技大會 於今（10）日舉辦會前記者會，本土製藥公司東生華(TW-8432)憑藉卓越表現，榮獲"2024傑出生技產業獎－潛力標竿獎"，彰顯其在生技領域的創新實力與發展潛力。東生華總經理楊思源表示，這歸功於三個維度的策略奏效。 第一個維度是開發利基型產品，透過Double雙引擎策略，聚焦自製國產新藥外銷和早期研發品項國外授權，加速業績成長。 第二個維度聚焦於深耕台灣市場並擴張亞洲版圖。 第三個維度聚焦於無機、有機雙成長。 總經理楊思源對此次獲獎表示感謝，並強調這不僅是對東生華過去努力的肯定，更是公司未來發展的動力。她表示：「東生華將繼續秉持創新精神，突破技術瓶頸，為患者提供更優質、全面的醫療解決方案。」 東生華將堅持 #以病患為中心，致力滿足尚未被滿足的醫療需求。開發更多創新醫療組合，積極拓展海外市場，推動集團全球化發展。東生華將成為 #國際創新生技公司在亞洲地區開發及行銷的最佳策略夥伴。 7/25～7/28 東生華在 #2024BIOAsiaTaiwan 亞洲生技大會 歡迎蒞臨 #M304 攤位與我們相會！

🎉🎉🎉東生華榮獲 #2024傑出生技產業獎 #潛力標竿獎 三大策略推動創新發展‼ #2024亞洲生技大會 於今（10）日舉辦會前記者會，本土製藥公司東生華(TW-8432)憑藉卓越表現，榮獲"2024傑出生技產業獎－潛力標竿獎"，彰顯其在生技領域的創新實力與發展潛力。東生華總經理楊思源表示，這歸功於三個維度的策略奏效。 第一個維度是開發利基型產品，透過Double雙引擎策略，聚焦自製國產新藥外銷和早期研發品項國外授權，加速業績成長。 第二個維度聚焦於深耕台灣市場並擴張亞洲版圖。 第三個維度聚焦於無機、有機雙成長。 總經理楊思源對此次獲獎表示感謝，並強調這不僅是對東生華過去努力的肯定，更是公司未來發展的動力。她表示：「東生華將繼續秉持創新精神，突破技術瓶頸，為患者提供更優質、全面的醫療解決方案。」 東生華將堅持 #以病患為中心，致力滿足尚未被滿足的醫療需求。開發更多創新醫療組合，積極拓展海外市場，推動集團全球化發展。東生華將成為 #國際創新生技公司在亞洲地區開發及行銷的最佳策略夥伴。 7/25～7/28 東生華在 #2024BIOAsiaTaiwan 亞洲生技大會 歡迎蒞臨 #M304 攤位與我們相會！